BYOOVIZ DEMONSTRATED A
COMPARABLE SAFETY PROFILE
TO LUCENTIS1,2

Summary of All Adverse Events up to Week 52
(Safety Set)2*

AE Summary
BYOOVIZ (n=350) n (%)
Lucentis (n=354) n (%)
  •  
  • Adapted from Bressler NM, et al., 2021.
  •  
  • Percentages are based on the number of participants in the safety set.
  • *
  • Included participants receiving at least one dose during the study period after randomization.
  • The most frequently reported adverse events of special interest were intraocular pressure increase (BYOOVIZ: 0.3%, n=1; Lucentis: 1.7%, n=6) and iridocyclitis (BYOOVIZ: 0.9%, n=3; Lucentis: 0%, n=0).
  •  

Additional safety, immunogenicity, and pharmacokinetic (PK) outcomes were comparable between treatment groups1 up to Week 52 of treatment2

  • ‡ PK data were obtained in 54 patients and have limitations in their interpretation. Absorption of intravitreal injection anti-VEGF product into systemic circulation is very limited.

  • AE=adverse event; AESI=adverse event of special interest; SAE=serious adverse event; TEAE=treatment-emergent adverse event; VEGF=vascular endothelial growth factor.